Efficacy of faricimab for polypoidal choroidal vasculopathy in the loading stage

doi:10.11958/20260828

Abstract

Abstract:

Objective To evaluate the efficacy of faricimab for polypoidal choroidal vasculopathy (PCV) in the loading stage. Methods A total of 23 patients (23 eyes) who were diagnosed with PCV in the ophthalmology department of our hospital from August 2024 to December 2025 and treated with faricimab were included in this study. The average age was (74.2±6.5) years, including 13 newly treated eyes and 10 treated eyes. All patients underwent faricimab therapy once a month for 3 consecutive months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT) and central choroidal thickness (CCT) were evaluated at baseline and after each therapy. Subsequent to the completion of the loading stage, the regression rates of polypoidal lesions (PL) and serous pigment epithelial detachment (PED), along with the proportion of patients with dry macula, were assessed. Results After the treatment, both the visual function and anatomic outcome of patients were improved significantly. The BCVA increased from the baseline of 0.68±0.27 to 0.50±0.29, 0.46±0.29 and 0.38±0.25 after three injections respectively (P<0.01), and the improvement persisted throughout the loading stage. CRT decreased from the baseline of (422.0±110.4) μm to (291.2±49.0) μm, (272.2±44.7) μm and (260.8±44.9) μm (P<0.01) ，and CCT decreased from (256.3±131.5) μm at baseline to (249.1±131.2) μm, (245.2±127.6) μm and (239.3±127.0) μm after three injections, respectively (P<0.01). After the loading stage, the regression rate of PL was 47.8% (11/23), the regression rate of serous PED was 73.3% (11/15) and the proportion of dry macula was 78.3% (18/23). There were no adverse drug events in this study. Conclusion After faricimab loading phase treatment, the anatomical and vision functions of PCV patients improve significantly, especially in the regression of PL.

Key words: choroid diseases, polyps, vascular diseases, treatment outcome, faricimab, polypoidal lesion

CLC Number:

R774.1

Figures/Tables 1

References 23

[1]	Yang Z, Zhang W, Gu X, et al. Polypoidal choroidal vasculopathy: In-depth insights and promising future directions[J]. Prog Retin Eye Res, 2026, 110:101414. doi:10.1016/j.preteyeres.2025.101414.
[2]	Cheung C, Lai T, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy:definition,pathogenesis,diagnosis,and management[J]. Ophthalmology, 2018, 125(5):708-724. doi:10.1016/j.ophtha.2017.11.019.
[3]	Koh A, Lee W K, Chen L J, et al. EVEREST study:efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy[J]. Retina, 2012, 32(8):1453-1464. doi:10.1097/IAE.0b013e31824f91e8.
[4]	Koh A H, Expert PCV Panel, Chen L J, et al. Polypoidal choroidal vasculopathy:evidence-based guidelines for clinical diagnosis and treatment[J]. Retina, 2013, 33(4):686-716. doi:10.1097/IAE.0b013e3182852446.
[5]	Cho H J, Kim K M, Kim H S, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2016, 165:1-6. doi:10.1016/j.ajo.2016.02.019.
[6]	Wong T Y, Ogura Y, Lee W K, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy:two-year results of the aflibercept in polypoidal choroidal vasculopathy study[J]. Am J Ophthalmol, 2019, 204:80-89. doi:10.1016/j.ajo.2019.02.027.
[7]	Lee W K, Wong T Y, Chen S J, et al. Aflibercept 8 mg in polypoidal choroidal vasculopathy:post hoc analysis of the PULSAR randomized clinical trial[J]. JAMA Ophthalmol, 2026, 144(2):129-137. doi:10.1001/jamaophthalmol.2025.5098.
[8]	Regula J T, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases[J]. EMBO Mol Med, 2016, 8(11):1265-1288. doi:10.15252/emmm.201505889.
[9]	Sharma A, Kumar N, Kuppermann B D, et al. Faricimab: expanding horizon beyond VEGF[J]. Eye(Lond), 2020, 34(5):802-804. doi:10.1038/s41433-019-0670-1.
[10]	Lee J, Cheung G, Chenet S J, et al. Faricimab for polypoidal choroidal vasculopathy:week 16 results from the phase 3b/4 SALWEEN trial[J]. Invest Ophthalmol Vis Sci, 2025, 66(8):1859.
[11]	Ruamviboonsuk P, Ng D, Chaikitmongkol V, et al. Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy(PCV)from the Asia-Pacific Vitreo-retina Society (APVRS)[J]. Asia Pac J Ophthalmol (Phila), 2025, 14(1):100144. doi:10.1016/j.apjo.2025.100144.
[12]	Teo K, Gillies M, Fraser-Bell S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy:a subtype of neovascular age-related macular degeneration[J]. Int J Mol Sci, 2018, 19(9):2611. doi:10.3390/ijms19092611.
[13]	Wong C W, Wong T Y, Cheung C M. Polypoidal choroidal vasculopathy in Asians[J]. J Clin Med, 2015, 4(5):782-821. doi:10.3390/jcm4050782.
[14]	Joussen A M, Ricci F, Paris L P, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases:a review of preclinical data[J]. Eye(Lond), 2021, 35(5):1305-1316. doi:10.1038/s41433-020-01377-x.
[15]	Heier J S, Khanani A M, Quezada Ruiz C, et al. Efficacy, durability,and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE):two randomised,double-masked,phase 3,non-inferiority trials[J]. Lancet, 2022, 399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1.
[16]	Otani A, Takagi H, Oh H, et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes[J]. Invest Ophthalmol Vis Sci, 1999, 40(9):1912-1920.
[17]	Ma L, Brelen M E, Tsujikawa M, et al. Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations[J]. Invest Ophthalmol Vis Sci, 2017, 58(2):1076-1083. doi:10.1167/iovs.16-20575.
[18]	Zhang C, Zhang W, Wang T, et al. Polypoidal choroidal vasculopathy:from clinicopathological and molecular perspectives[J]. Ophthalmic Res, 2025, 68(1):521-530. doi:10.1159/000548709.
[19]	Cho J, Han H Y, Park S, et al. One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy:a comparative study[J]. Eye(Lond), 2026, 39(16):2893-2898. doi:10.1038/s41433-025-03980-2.
[20]	Mukai R, Kataoka K, Tanaka K, et al. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan[J]. Sci Rep, 2024, 14(1):11681. doi:10.1038/s41598-024-62559-1.
[21]	Tanaka A, Hata M, Tsuchikawa M, et al. Short-term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration[J]. Clin Ophthalmol, 2024, 18:507-516. doi:10.2147/OPTH.S448507.
[22]	Arnold-Vangsted A, Schou M G, Balaratnasingam C, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy:A systematic review and meta-analysis[J]. Acta Ophthalmol, 2025, 103(3):247-256. doi:10.1111/aos.16797.
[23]	Kim H M, Woo S J. Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs[J]. Curr Ther Res Clin Exp, 2024, 100:100742. doi:10.1016/j.curtheres.2024.100742.

时间点	BCVA（n=23）	CRT/μm（n=23）	CCT/μm（n=20）
治疗前	0.68±0.27	422.0±110.4	256.3±131.5
1针后	0.50±0.29^a	291.2±49.0^a	249.1±131.2^a
2针后	0.46±0.29^a	272.2±44.7^a	245.2±127.6^a
3针后	0.38±0.25^a	260.8±44.9^a	239.3±127.0^a
F	26.180^＊＊	27.591^＊＊	677.700^＊＊

时间点	BCVA（n=23）	CRT/μm（n=23）	CCT/μm（n=20）
治疗前	0.68±0.27	422.0±110.4	256.3±131.5
1针后	0.50±0.29^a	291.2±49.0^a	249.1±131.2^a
2针后	0.46±0.29^a	272.2±44.7^a	245.2±127.6^a
3针后	0.38±0.25^a	260.8±44.9^a	239.3±127.0^a
F	26.180^＊＊	27.591^＊＊	677.700^＊＊